Trial Profile

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neflamapimod (Primary)
Indications Dementia; Lewy body disease
Focus Adverse reactions; Pharmacokinetics
Sponsors EIP Pharma

Most Recent Events

17 Mar 2025 According to the CervoMed media release, Initial safety, biomarker and pharmacokinetic data from an ongoing trial in patients with being treated with a twice daily regimen (80mg BID) of neflamapimod is expected to be available in the fourth quarter of 2025.
07 Mar 2025 The protocol has been Amended to change the primary endpoint and hence the overall trial focus has also been changed to AR and PK. Indication has also been changed.
14 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com